Pharmacogenetics of Ribavirin-Induced Anemia in Hepatitis C

References

• Maxmen A . Pharmacogenomics: playing the odds . Nature474 ( 7350 ), 9 – 10 ( 2011 ).
   Web of Science ®Google Scholar
• Ge D , FellayJ , ThompsonAJet al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance . Nature461 ( 7262 ), 399 – 401 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Suppiah V , MoldovanM , AhlenstielGet al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy . Nat. Genet.41 ( 10 ), 1100 – 1104 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Tanaka Y , NishidaN , SugiyamaMet al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C . Nat Genet.41 ( 10 ), 1105 – 1109 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Fellay J , ThompsonAJ , GeDet al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C . Nature464 ( 7267 ), 405 – 408 ( 2010 ).
   PubMedGoogle Scholar
• Ampuero J , Del CampoJA , RojasLet al. Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection . Genes Immun.16 ( 5 ), 297 – 300 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Manzano-Robleda MC , Ornelas-ArroyoV , Barrientos-GutiérrezT , Méndez-SánchezN , UribeM , Chávez-TapiaNC . Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis . Ann. Hepatol.14 ( 1 ), 46 – 57 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shahid I , AlmalkiWH , HafeezMH , HassanS . Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies . Crit. Rev. Microbiol.6 , 1 – 13 ( 2014 ).
   Google Scholar
• Hézode C . Management of anaemia and other treatment complications . Dig. Liver Dis.45 ( 5 ), 337 – 342 ( 2013 ).
   Google Scholar
• Stättermayer AF , ScherzerT , BeinhardtS , RutterK , HoferH , FerenciP . Review article: genetic factors that modify the outcome of viral hepatitis . Aliment Pharmacol. Ther.39 ( 10 ), 1059 – 1070 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Fülöp B , MihmU , RohdePet al. Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type . J. Viral Hepat. doi:10.1111/jvh.12562 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM , DahariH , NeumannAUet al. Antiviral action of ribavirin in chronic hepatitis C . Gastroenterology126 ( 3 ), 703 – 714 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH , SeeffLB . Peginterferon and ribavirin for chronic hepatitis C . N. Engl. J. Med.355 ( 23 ), 2444 – 2451 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Younossi Z , KallmanJ , KincaidJ . The effects of HCV infection and management on health-related quality of life . Hepatology45 ( 3 ), 806 – 816 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Russmann S , GrattaglianoI , PortincasaP , PalmieriVO , PalascianoG . Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research . Curr. Med. Chem.13 ( 27 ), 3351 – 3357 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Thompson AJ , McHutchisonJG . Antiviral resistance and specifically targeted therapy for HCV (STAT-C) . J. Viral. Hepat.16 ( 6 ), 377 – 387 ( 2009 ).
   PubMedGoogle Scholar
• Bacon B , GordonSC , LawitzEet al. Boceprevir for previously treated chronic HCV genotype 1 infection . N. Engl. J. Med.364 ( 13 ), 1207 – 1217 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sherman KE , FlammSL , AfdhalNHet al. Response-guided telaprevir combination treatment or hepatitis C virus infection . N. Engl. J. Med.364 ( 11 ), 1014 – 1024 ( 2011 ).
   Google Scholar
• Salmerón J , VinaixaC , BerenguerRet al. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis . World J. Gastroenterol.21 ( 30 ), 9163 – 9174 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Jacobson I , McHutchisonJ , DusheikoGet al. Telaprevir for previously untreated chronic hepatitis C virus infection . N. Engl. J. Med.364 ( 25 ), 2405 – 2416 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Poordad F , McConeJ , BaconBRet al. Boceprevir for untreated chronic HCV genotype 1 infection . N. Engl. J. Med.364 ( 13 ), 1195 – 1206 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS , PoordadF , MannsMPet al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the SPRINT-2 trial . Hepatology57 ( 3 ), 974 – 984 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Koh C , LiangTJ . What is the future of ribavirin therapy for hepatitis C?Antiviral Res.104 , 34 – 39 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ampuero J , Romero-GomezM . HCV: current, and evolving, treatments for genotypes 2 and 3 . Gastroenterol. Clin. North Am.44 ( 4 ), 845 – 857 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ampuero J , Romero-GómezM , ReddyKR . Review article: HCV genotype 3 – the new treatment challenge . Aliment Pharmacol. Ther.39 ( 7 ), 686 – 698 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA HCV Guidance Panel . Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus . Hepatology62 ( 3 ), 932 – 954 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Rotman Y , NoureddinM , FeldJJet al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C . Gut63 ( 1 ), 161 – 169 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Soota K , MaliakkalB . Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection . World J. Gastroenterol.20 ( 43 ), 16184 – 16190 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Testoni B , LevreroM , DurantelD . Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question?Gut63 ( 1 ), 3 – 4 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS , ShiffmanML , AfdhalNHet al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate . Gastroenterology139 ( 5 ), 1602 – 1611 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Reau N , HadziyannisSJ , MessingerD , FriedMW , JensenDM . Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon-alfa-2a (40KD) plus ribavirin . Am. J. Gastroenterol.103 ( 8 ), 1981 – 1988 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M , BerenguerM , MolinaE , CallejaJL . Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations . J. Hepatol.59 ( 6 ), 1323 – 1330 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• De Franceschi L , FattovichG , TurriniFet al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage . Hepatology31 ( 4 ), 997 – 1004 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Hitomi Y , CirulliET , FellayJet al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function . Gastroenterology140 , 1314 – 1321 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• von Ahsen N , OellerichM , ArmstrongVW . Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype–phenotype correlation and promoter function . Ther. Drug Monit.30 , 16 – 22 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Thompson AJ , FellayJ , PatelKet al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction . Gastroenterology139 ( 4 ), 1181 – 1189 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Patil SD , NgoLY , GlueP , UnadkatJD . Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter . Pharm. Res.15 ( 6 ), 950 – 952 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Endres CJ , MossAM , KeBet al. The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes . J. Pharmacol. Exp. Ther.329 ( 1 ), 387 – 398 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cusato J , AllegraS , BoglioneLet al. VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia . Pharmacogenet. Genomics25 ( 4 ), 164 – 172 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Trinks J , HulaniukML , RedalMA , FlichmanD . Clinical utility of pharmacogenomics in the management of hepatitis C . Pharmgenomics Pers. Med.7 , 339 – 347 ( 2014 ).
   PubMedGoogle Scholar
• Tanaka Y , KurosakiM , NishidaNet al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C . Hum. Mol. Genet.20 ( 17 ), 3507 – 3516 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Clark PJ , AghemoA , DegasperiEet al. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy . J. Viral. Hepat.20 ( 12 ), 858 – 866 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Holmes JA , RobertsSK , AliRJet al. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response . Hepatology59 ( 6 ), 2152 – 2160 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Matsuura K , TanakaY , WatanabeTet al. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type . J. Viral. Hepat.21 ( 7 ), 466 – 474 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rembeck K , WaldenströmJ , HellstrandKet al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3 . Hepatology59 ( 6 ), 2131 – 2139 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Peltenburg NC , BakkerJA , VroemenWHet al. Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype . Clin. Chem. Lab. Med.53 ( 12 ), 2021 – 2029 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ogawa E , FurusyoN , NakamutaMet al. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy . J. Hepatol.59 ( 4 ), 667 – 674 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Chayama K , HayesCN , AbeHet al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C . J. Infect. Dis.204 ( 1 ), 84 – 93 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Aghemo A , GrassiE , RumiMGet al. Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir . PLoS ONE9 ( 4 ), e95881 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lupo F , RussoR , IolasconAet al. Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients . Liver Int.36 ( 1 ), 49 – 58 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Poordad F , LawitzE , ReddyKRet al. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection – a randomized trial . Gastroenterology145 ( 5 ), 1035 – 1044 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Tahata Y , HiramatsuN , OzeTet al. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin . J. Gastroenterol.51 ( 3 ), 252 – 259 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Morio K , ImamuraM , KawakamiYet al. ITPA polymorphism effects on decrease of hemoglobin during simeprevir, pegylated interferon and ribavirin combination treatment for chronic hepatitis C . Hepatol. Res. doi:10.1111/hepr.12681 ( 2016 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Doehring A , HofmannWP , SchleckerCet al. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C . Pharmacogenet. Genomics21 ( 5 ), 289 – 296 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Rau M , StickelF , RussmannSet al. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection . J. Hepatol.58 ( 4 ), 669 – 675 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ampuero J , Del CampoJA , RojasLet al. Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment . J. Clin. Virol.68 , 56 – 60 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Milazzo L , PeriAM , MazzaliCet al. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir . J. Antimicrob. Chemother.70 ( 4 ), 1155 – 1160 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lombardi A , LandonioS , MagniCet al. ITPA and SLC29A1 genotyping for the prediction of ribavirin dose reduction in anti-HCV triple therapy with protease inhibitors . Pharmacology96 ( 3 ), 163 – 166 ( 2015 ).
   PubMed Web of Science ®Google Scholar